Disease · MONDO_0002280

anemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anemia. Diseases, record MONDO_0002280. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002280

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anemia; Open Targets
Open Targets ID: MONDO_0002280; Open Targets
Other names: Anaemia, Low number of red blood cells or haemoglobin, Low number of red blood cells or hemoglobin, anaemia (disease), anemia (disease); Open Targets
Disease Ontology: DOID:2355; Disease Ontology
MeSH: D000740; MeSH
NCI Thesaurus: C2869; NCI Thesaurus
Highest stage of its drugs: Approval, for 44 of its 172 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs172

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPOETIN ALFA	CHEMBL1201565	Protein	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	97	89	56	Drugs and targets
DARBEPOETIN ALFA	CHEMBL1201566	Protein	Approval	DailyMed, EMA Human Drugs and TTD	78	72	49	Drugs and targets
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Approval	DailyMed	50	49	22	Drugs and targets
EPOETIN BETA	CHEMBL2109092	Protein	Approval	EMA Human Drugs	45	43	13	Drugs and targets
ROXADUSTAT	CHEMBL2338329	Small molecule	Approval	EMA Human Drugs	34	32	32	Drugs and targets
DAPRODUSTAT	CHEMBL3544988	Small molecule	Approval	FDA and TTD	26	23	23	Drugs and targets
LUSPATERCEPT	CHEMBL3039545	Protein	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	18	13	13	Drugs and targets
METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	CHEMBL3707314	Protein	Approval	DailyMed and EMA Human Drugs	13	11	8	Drugs and targets
VADADUSTAT	CHEMBL3646221	Small molecule	Approval	EMA Human Drugs and FDA	13	10	10	Drugs and targets
FOLIC ACID	CHEMBL1622	Small molecule	Approval	DailyMed	6	5	5	Drugs and targets

1 to 10 of 172

See all 172 drugs

Targets138

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	14	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
EPOR	Erythropoietin receptor	10	Erythropoietin receptor agonist	Approval	https://conductscience.org/library/genes/2057	Drugs and targets
EGLN1	Egl nine homolog 1	5	Egl nine homolog 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/54583	Drugs and targets
EGLN2	Hypoxia-inducible factor prolyl hydroxylase	4	Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/112398	Drugs and targets
EGLN3	Hypoxia-inducible factor prolyl hydroxylase	4	Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase inhibitor	Approval	https://conductscience.org/library/genes/112399	Drugs and targets
IFNAR1	Interferon alpha/beta receptor	4	Interferon alpha/beta receptor agonist	Investigational new drug	https://conductscience.org/library/genes/3454	Drugs and targets
IFNAR2	Interferon alpha/beta receptor	4	Interferon alpha/beta receptor agonist	Investigational new drug	https://conductscience.org/library/genes/3455	Drugs and targets
PGR	Progesterone receptor	4	Progesterone receptor agonist; Progesterone receptor modulator	Phase 3	https://conductscience.org/library/genes/5241	Drugs and targets
ADRB1	Adrenergic receptor	3	Adrenergic receptor agonist; Beta-1 adrenergic receptor agonist	Unknown	https://conductscience.org/library/genes/153	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	3	CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator	Approval	https://conductscience.org/library/genes/51185	Drugs and targets

1 to 10 of 138

See all 138 targets

Trials332

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 47 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02876835	Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)	Phase 3	3,872	2022-04-14	Anaemia	DAPRODUSTAT, DARBEPOETIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT02879305	Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)	Phase 3	2,964	2021-12-03	Anaemia, Aspergillosis, Allergic Bronchopulmonary	DAPRODUSTAT	Its record names the disease	ClinicalTrials.gov
NCT00773513	A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)	Phase 4	2,825	2018-08-15	Chronic Renal Anemia	DARBEPOETIN ALFA, EPOETIN ALFA, EPOETIN BETA, METHOXY POLYETHYLENE GLYCOL-EPOETIN BETA	Its record names the disease	ClinicalTrials.gov
NCT00632125	Post-authorization Safety Study in CKD Subjects Receiving HX575 i.v.	Phase 4	1,695	2017-07-11	Chronic Kidney Disease	EPOETIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT01809314	An Observational Study of Epoetin Beta (NeoRecormon) in Participants With Cancer Receiving Chemotherapy		1,167	2016-08-19	Anemia	EPOETIN BETA	Its record names the disease	ClinicalTrials.gov
NCT01168349	An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)		1,060	2015-10-02	Anemia, Neoplasms	EPOETIN BETA	Its record names the disease	ClinicalTrials.gov
NCT02052310	Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants	Phase 3	1,043	2021-10-01	Anemia in Incident Dialysis Patients	EPOETIN ALFA, ROXADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT01750190	A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis	Phase 3	922	2021-10-01	CKD Anemia	ROXADUSTAT	Its record names the disease	ClinicalTrials.gov
NCT01652872	Strategies Using Darbepoetin Alfa to Avoid Transfusions in Chronic Kidney Disease	Phase 3	756	2018-11-08	Anemia in Chronic Kidney Disease Patients Not on Dialysis	DARBEPOETIN ALFA	Its record names the disease	ClinicalTrials.gov
NCT02273726	Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis	Phase 3	741	2021-10-29	CKD Anemia in Stable Dialysis Patients	EPOETIN ALFA, ROXADUSTAT	Its record names the disease	ClinicalTrials.gov

1 to 10 of 332

See all 332 trials

Comparisons in its trials168

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Daprodustat vs Darbepoetin Alfa: Number of Participants With at Least One BP Exacerbation Event During Study	939 of 1,919	1,012 of 1,884	3,803	NCT02876835	Trial comparisons
Daprodustat vs Darbepoetin Alfa: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)	1,167 of 1,491	1,063 of 1,520	3,011	NCT02876835	Trial comparisons
Daprodustat vs rhEPO: deaths from any cause	294 of 1,487	300 of 1,477	2,964	NCT02879305	Trial comparisons
Daprodustat vs rhEPO: serious adverse events	773 of 1,482	748 of 1,474	2,956	NCT02879305	Trial comparisons
Daprodustat vs rhEPO: Number of Participants With at Least One BP Exacerbation Event During Study	1,191 of 1,480	1,186 of 1,470	2,950	NCT02879305	Trial comparisons
Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause	557 of 1,409	558 of 1,409	2,818	NCT00773513	Trial comparisons
Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events	1,123 of 1,409	1,097 of 1,409	2,818	NCT00773513	Trial comparisons
Daprodustat vs rhEPO: Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)	903 of 1,238	866 of 1,247	2,485	NCT02879305	Trial comparisons
Roxadustat vs Epoetin Alfa: deaths from any cause	64 of 522	54 of 517	1,039	NCT02052310	Trial comparisons
Roxadustat vs Epoetin Alfa: serious adverse events	234 of 522	218 of 517	1,039	NCT02052310	Trial comparisons

1 to 10 of 168

See all 168 comparisons in its trials

Papers from its trials193

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40225393	RESULT	1	PubMed
39844769	RESULT	1	PubMed
39022429	RESULT	1	PubMed
38530913	RESULT	1	PubMed
37954906	RESULT	2	PubMed
37592715	RESULT	1	PubMed
37299583	RESULT	1	PubMed
35905974	RESULT	1	PubMed
35011099	RESULT	1	PubMed
35002031	RESULT	1	PubMed

1 to 10 of 193

See all 193 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002280

GET https://conductscience.org/api/diseases/v1/MONDO_0002280/drugs?page=2

API reference For AI assistants